Ocular Oncology

CARLSBAD, Calif. — Patients with uveal melanoma who had Medicaid or no insurance were less likely to receive brachytherapy and more likely to be diagnosed at later stages, according to a study presented here.

WAILEA, Hawaii — The world of melanoma has changed a lot in recent years and more change is yet to come, according to a speaker at Hawaiian Eye 2024.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial assessing belzupacap sarotalocan, according to a press release.

SAN FRANCISCO — Telemedicine has the potential to drive ocular oncology forward, but there are barriers that must be addressed first, according to a speaker here.

In this Healio Video Perspective from the Retina Society meeting, Carol Shields, MD, describes an interesting case she saw in her office.

Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.

The FDA granted orphan drug designation to IOA-244 for the treatment of uveal melanoma, according to a press release from iOnctura.

NEW YORK — In a presentation at OSN New York Retina, Jasmine H. Francis, MD, FACS, offers insights for retina surgeons on distinguishing between malignant and benign tumors.

The FDA granted de novo classification to the SeCore CDx HLA Sequencing System for use as a companion diagnostic with Kimmtrak for metastatic or unresectable uveal melanoma, according to a Thermo Fisher Scientific press release.

CHICAGO — AU-011 helped preserve vision in patients with early-stage choroidal melanoma, according to a study presented at the American Academy of Ophthalmology meeting.